HLB SCIENCE Inc.

A343090

KR7343090007

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
3,400 ^KRW	-1.73%		+8.63%	+32.81%

2023	HLB SCIENCE Inc. announced that it has received KRW 6.000000045 billion in funding from HLB Life Science Co., Ltd.	CI
2023	HLB SCIENCE Inc. announced that it expects to receive KRW 6.000000045 billion in funding from HLB Life Science Co., Ltd.	CI

DandiBioscience, Inc. announced that it has received KRW 8.4 billion in funding

July 06, 2021

On July 7, 2021, DandiBioscience, Inc. (XKON:A343090) closed the transaction.

Latest news about HLB SCIENCE Inc.

HLB SCIENCE Inc. announced that it has received KRW 6.000000045 billion in funding from HLB Life Science Co., Ltd.	23-09-25	CI
HLB SCIENCE Inc. announced that it expects to receive KRW 6.000000045 billion in funding from HLB Life Science Co., Ltd.	23-09-17	CI
HLB SCIENCE Inc. announced that it has received KRW 5.0000004 billion in funding from HLB bioStep Co.,Ltd.	23-02-08	CI
HLB SCIENCE Inc. announced that it expects to receive KRW 5.0000004 billion in funding from HLB bioStep Co.,Ltd.	23-01-31	CI
DandiBioscience, Inc. announced that it has received KRW 8.4 billion in funding	21-07-06	CI
DandiBioscience, Inc. announced that it expects to receive KRW 8.4 billion in funding	21-06-14	CI
DandiBioscience, Inc. announced that it has received KRW 1.3 billion in funding	21-04-21	CI
DandiBioscience, Inc. announced that it expects to receive KRW 1.3 billion in funding	21-04-15	CI
NEXT SCIENCE Co.,Ltd. cancelled the acquisition of 45.4% stake in Dandi Bioscience Inc.	19-10-04	CI
Dandi Bio Science Co.,Ltd. announced that it has received KRW 4.164081 billion in funding from Next Science Co., Ltd.	19-03-27	CI
Dandi Bio Science Co.,Ltd. announced that it expects to receive KRW 4.164081 billion in funding from NEXT SCIENCE Co.,Ltd.	19-02-21	CI
Next Science In Talks To Acquire Dandi Bioscience	18-10-05	CI
NEXT SCIENCE Co.,Ltd. agreed to acquire 45.4% stake in Dandi Bioscience Inc. for KRW 6.3 billion.	18-10-04	CI

HLB Science Inc, formerly DanDi Bioscience Inc, is a Korea-based company principally engaged in the research and development of biological pharmaceuticals. The Company is engaged in the research and development of sepsis treatment, antibiotics for super bacteria, dementia treatment, dementia diagnostic kits and other medicines products.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
HLB SCIENCE INC.	+32.81%	40.24M
VERTEX PHARMACEUTICALS INCORPORATED	-2.61%	102B
REGENERON PHARMACEUTICALS, INC.	+2.29%	96.09B
ARGENX SE	+2.13%	22.28B
BIONTECH SE	-17.06%	21.4B
GENMAB A/S	-8.79%	18.14B
WUXI APPTEC CO., LTD.	-39.98%	17.02B
BEIGENE, LTD.	-13.83%	16.09B
NEUROCRINE BIOSCIENCES, INC.	+6.43%	13.83B
SAREPTA THERAPEUTICS, INC.	+32.70%	11.97B

Bio Therapeutic Drugs

HLB SCIENCE Inc.

Equities

A343090

KR7343090007

Biotechnology & Medical Research

DandiBioscience, Inc. announced that it has received KRW 8.4 billion in funding

Latest news about HLB SCIENCE Inc.

Chart HLB SCIENCE Inc.

Company Profile

Sector Bio Therapeutic Drugs